8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cardiovascular

Kobayashi- Sun J, Kobayashi I, Kashima M, Hirayama J, Kakikawa M, Yamada S, Suzuki N

Bioeffects Seen

Authors not listed · 2024

Share:

This cardiovascular drug study was misclassified as EMF research, highlighting database accuracy issues.

Plain English Summary

Summary written for general audiences

This appears to be a misclassified study about alirocumab, a cholesterol-lowering medication, not EMF research. The ODYSSEY OUTCOMES trial followed over 47,000 patients and found the drug reduced cardiovascular events and death compared to placebo, with minimal side effects beyond injection site reactions.

Why This Matters

This study has been incorrectly categorized in our EMF database - it's actually cardiovascular research about a cholesterol medication called alirocumab. This type of misclassification highlights an important issue in EMF research: the need for rigorous study selection and proper categorization. While this particular study offers no insights into electromagnetic field health effects, it does demonstrate the gold standard for clinical research that we rarely see in EMF studies. The ODYSSEY trial included over 47,000 patient-years of observation with proper placebo controls - the kind of large-scale, long-term study design that's desperately needed in EMF health research. Unfortunately, most EMF studies involve far smaller sample sizes and shorter observation periods, making it difficult to establish definitive health effects.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2024). Kobayashi- Sun J, Kobayashi I, Kashima M, Hirayama J, Kakikawa M, Yamada S, Suzuki N.
Show BibTeX
@article{kobayashi_sun_j_kobayashi_i_kashima_m_hirayama_j_kakikawa_m_yamada_s_suzuki_n_ce4084,
  author = {Unknown},
  title = {Kobayashi- Sun J, Kobayashi I, Kashima M, Hirayama J, Kakikawa M, Yamada S, Suzuki N},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae025},
  
}
DOI: 10.1093/ehjcvp/pvae025PubMed: 38658193

Quick Questions About This Study

This appears to be a database classification error. The study examines alirocumab, a cholesterol-lowering medication, not electromagnetic field exposure. Such misclassifications can occur when automated systems incorrectly categorize research papers based on keywords or metadata.
The trial studied whether alirocumab, a cholesterol-lowering injection, reduces heart attacks and strokes in high-risk patients. Over 47,000 patients were followed, showing significant reductions in cardiovascular events and death compared to placebo treatment.
The ODYSSEY OUTCOMES trial provided at least 5 years of safety data on alirocumab. This long-term follow-up demonstrated the medication's safety profile was essentially identical to placebo except for minor injection site reactions.
Alirocumab showed virtually identical side effects to placebo, with only a 1.7% absolute increase in local injection site reactions. Laboratory abnormalities and adverse events occurred at similar rates in both treatment and placebo groups.
Yes, the study specifically examined vulnerable populations including elderly patients, diabetics, stroke survivors, and those with kidney disease. Alirocumab demonstrated similar safety and effectiveness across all these high-risk groups compared to the general study population.